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Background: Pirfenidone is a novel anti-fibrotic and anti-inflammatory agent that inhibits the progression of
fibrosis in animal models and in patients with idiopathic pulmonary fibrosis (IPF). We previously showed that
pirfenidone inhibits the over-expression of collagen type I and of heat shock protein (HSP) 47, a collagen-specific
molecular chaperone, in human lung fibroblasts stimulated with transforming growth factor (TGF)-β1 in vitro. The
increased numbers of HSP47-positive type II pneumocytes as well as fibroblasts were also diminished by
pirfenidone in an animal model of pulmonary fibrosis induced by bleomycin. The present study evaluates the
effects of pirfenidone on collagen type I and HSP47 expression in the human alveolar epithelial cell line, A549 cells
in vitro.
Methods: The expression of collagen type I, HSP47 and E-cadherin mRNAs in A549 cells stimulated with TGF-β1
was evaluated by Northern blotting or real-time PCR. The expression of collagen type I, HSP47 and fibronectin
proteins was assessed by immunocytochemical staining.
Results: TGF-β1 stimulated collagen type I and HSP47 mRNA and protein expression in A549 cells, and pirfenidone
significantly inhibited this process. Pirfenidone also inhibited over-expression of the fibroblast phenotypic marker
fibronectin in A549 cells induced by TGF-β1.
Conclusion: We concluded that the anti-fibrotic effects of pirfenidone might be mediated not only through the
direct inhibition of collagen type I expression but also through the inhibition of HSP47 expression in alveolar
epithelial cells, which results in reduced collagen synthesis in lung fibrosis. Furthermore, pirfenidone might partially
inhibit the epithelial-mesenchymal transition.
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Idiopathic pulmonary fibrosis (IPF) is a progressive and
fatal disorder characterized by patchy fibrotic areas with
fibroblast proliferation and extracellular matrix remodel-
ing that results in irreversible distortion of the lung
architecture. The underlying molecular mechanisms
through which excessive collagen is deposited in fibrotic
lesions are not fully understood. The pathological* Correspondence: nsakamot@nagasaki-u.ac.jp
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reproduction in any medium, provided the orfeatures of IPF include scattered fibroblast foci that con-
sist of aggregates of mesenchymal cells, and which are
associated with the progression of fibrosis [1]. Although
resident fibroblasts probably expand in response to in-
jury, recent studies support the notion that lung fibro-
blast development might also be derived from bone
marrow and/or epithelial cells [2]. The alveolar epithelial
to mesenchymal transition (EMT) has been studied in
detail from the viewpoint of the pathogenesis of lung, as
well as renal fibrosis [2-5]. Alveolar epithelial cells are
also the primary source of mediators such as platelet-
derived growth factor, transforming growth factoral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ive tissue growth factor that can induce fibroblast migra-
tion, proliferation and activation [6]. Thus, alveolar
epithelial cells as well as fibroblasts are important in the
pathogenesis of lung fibrosis.
Pirfenidone is a novel antifibrotic agent that inhibits
the progression of lung, kidney and hepatic fibrosis in
experimental models [7-13]. This drug also exerts anti-
inflammatory properties including the regulation of key
growth factors and cytokines [10,11,14-16], and recent
clinical trials have revealed its therapeutic effects in
patients with IPF [17-19]. However, the exact mechan-
isms through which pirfenidone offers protection against
lung fibrosis remain unclear. In this context, we recently
found that pirfenidone inhibits the expression of colla-
gen type I and heat shock protein (HSP) 47, a collagen-
specific molecular chaperone, in TGF-β-stimulated
human lung fibroblasts in vitro [20]. Using a mouse
model of bleomycin-induced pulmonary fibrosis, we also
discovered that pirfenidone inhibits HSP47 over-
expression in myofibroblasts and in type II pneumo-
cytes, especially in fibrotic lesions, and that this activity
is concomitant with an obvious reduction in fibrosis
[12]. HSP47 is localized in the endoplasmic reticulum
that participates in the intracellular processing, folding,
assembly and secretion of procollagens [21-23]. Irre-
spective of the tissue site and organ, HSP47 expression
is always induced during the process of fibrosis, particu-
larly in and around fibrotic lesions [12,24,25]. Therefore,
HSP47-positive cells, especially myofibroblasts, might
play a central role in the synthesis, deposition and re-
modeling of the ECM in pulmonary fibrosis in both
patients and in animal models [12,26,27]. In this context,
collagen type I and HSP47 expression is recently consid-
ered to be one of the useful parameters for recognizing
EMT [28]. However, the specific effects of pirfenidone
upon collagen and HSP47 synthesis and EMT in alveolar
epithelial cells in vitro remain obscure.
To clarify the association between alveolar epithelial
cells and lung fibrosis and the action of pirfenidone
in vitro, we examined the expression of collagen type I
and HSP47 in the human alveolar epithelial cell line,
A549, stimulated with TGF-β1.
Materials and methods
Cells and Reagents
The human type II alveolar epithelial cell line, A549
(The American Type Culture Collection, Manassas, VA),
was maintained in Dulbecco's modified minimal essen-
tial medium (DMEM) containing 10% FBS and 2 mM L-
glutamine at 37 °C in a 5% CO2-humidified atmosphere.
All experiments proceeded using cells after 3–5 cell pas-
sages. Pirfenidone was provided by Shionogi & Co., Ltd
(Osaka, Japan). Recombinant human TGF-β1 (R&DSystems, Inc. Minneapolis, MN), was reconstituted in
4 mM HCl containing 0.1% bovine serum albumin
(BSA) to prepare a 1 μg/ml stock solution of active
growth factor. The stock solution was added to media to
yield various final concentrations of TGF-β1. To control
for nonspecific effects, cells were incubated in an equal
volume of 4 mM HCl and BSA solution was added to
the basal media.
Incubation of cells with pirfenidone and TGF-β1
Subcultures of A549 cells were seeded in 60-mm culture
dishes (BD FalconTM, Franklin Lakes, NJ) at a density of
1 × 105 per dish to analyze collagen type I and HSP47
mRNA expression and protein levels. When the cells
reached 70 - 80% confluence, the medium was replaced
with serum-free DMEM. The cells were subsequently
stimulated for 3, 6, 12, 24, 48 and 72 h with culture
medium alone (control) or with 100, 500 and 1000 μg/
ml of pirfenidone with or without 0.1, 1, 5, 10 ng/ml of
TGF-β1. Changes in cell morphology were also assessed
under phase contrast light microscopy.
RNA extraction and reverse-transcriptase PCR
Total RNA was isolated from the cells using the Qiagen
RNeasy Mini Kit (Qiagen, Valencia, CA) according to
the manufacturer's instructions. Samples were digested
with DNase I (Qiagen) to remove contaminating gen-
omic DNA. Isolated total RNA was analyzed using a DU
800 UV/Visible Spectrophotometer (Beckman Coulter,
Fullerton, CA). To generate complementary DNA
(cDNA), total RNA (5 μg) was reverse-transcribed using
the SuperScriptTM III first strand synthesis kit (Invitro-
gen, Carlsbad, CA) with oligo deoxythymidine as a pri-
mer. The reverse transcriptase reaction proceeded in a
total volume of 20 μl in a Gene Amp PCR system 9700
(Applied Biosystems, Foster City, CA) at 65 °C for 5
minutes, followed by 50 minutes at 42 °C and 15 min-
utes at 70 °C. Reaction volumes of 25 μl were placed in
96-well optical reaction plates with adhesive covers (ABI
PrismTM Applied Biosystems) using TaqManTM Univer-
sal PCR Master Mix (Applied Biosystems). Human beta-
actin (β-actin) served as the internal control. TaqMan
probes for human E-cadherin and β-actin were pur-
chased from Applied Biosystems. Samples were heated
to 95 °C for 10 min and then PCR amplification was
achieved by 40 cycles at 95 °C for 15 s and at 60 °C for
1 min using the ABI Prism 7500 (Applied Biosystems) as
described by the manufacturer. Real-time data were ana-
lyzed using the comparative CT method, where CT is the
cycle number at which the fluorescence reading is first
recorded above background levels. The comparative CT
and standard curve methods are similar except the
former uses the arithmetic formula, 2–ΔΔCT to achieve
relative quantification. A prior validation experiment
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mer/probe sets of the target genes and β-actin were ap-
proximately equal and within 0.1.Northern blotting
Samples were Northern blotted for collagen type I and
HSP47 as described [20,29]. Human HSP47 and
collagen-type I complementary DNAs (cDNAs) were
provided by the Institute for Frontier Medical Science,
Kyoto University, Japan. HSP47 mRNA was detected
using a 1.5 kilobase pair (kbp) EcoRI fragment of full-
length human HSP47 (CBP2) cDNA as a probe, whereas
collagen type I mRNA was detected using a 0.6 kbp
EcoRV fragment of full-length pCOLA1-I-CP cDNA as a
probe. The probes were labeled with 32P using a Ran-
dom Primer Labeling kit (Takara Biomedicals, Shiga,
Japan). Isolated RNAs (10 μg) were resolved by electro-
phoresis on 1% agarose gels containing 1.2% formalde-
hyde, transferred to a nylon membrane (HybondTM-N+,
Amersham International, Amersham, UK), and then sep-
arately hybridized with each 32P-labeled probe for 24 h
at 42 °C. Autoradiographed membranes were assessed
using a BAS5000 Bioimage Analyzer (Fuji Photo Film,
Japan). Relative transcription was normalized against
hybridization with a glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) probe.Figure 1 Time course of collagen type I (a) and HSP47 (c) mRNA expr
by Northern blotting. Collagen type I (b) and HSP47 (d) mRNA expression
with 5 and 10 ng/ml of TGF-β1, respectively. Density of mRNA and GAPDH
means ± SEM of four experiments. *P< 0.05, compared with control.Immunocytochemistry
After a 48-h incubation as detailed above, cultured cells
were fixed with acetone for 10 min and stained using
the alkaline phosphatase anti-alkaline phosphatase
method with goat anti-human collagen type I polyclonal
(CHEMICON, Temecula, CA), mouse anti-human
HSP47 (Stressgen, Victoria, Canada) and mouse anti-
cellular fibronectin monoclonal (CHEMICON) anti-
bodies. Negative controls included an irrelevant mouse
or goat IgG (Santa Cruz Biotechnology, Santa Cruz,
CA). The staining intensity of collagen type I and HSP47
in A549 cells was semi-quantified at × 400 magnification
in five fields using a grading score of 0 to 3 (0, 1, 2 and
3, corresponding to absent, weak, moderate and intense
staining, respectively). The total cell count was con-
verted to 100, so the maximum number was 300 in this
scoring system. The interobserver and intraobserver
variability in assessing the results was reproducible. Rep-
resentative results from one observer were statistically
analyzed.Statistical analysis
All values are expressed as means ± SEM. The minimum
number of replicates for all measurements was at least 3.
Differences between multiple groups were compared by
one-way analysis of variance. Dunnett's test served asession in A549 cells incubated with 5 ng/ml of TGF-β1 analyzed
was significantly increased in A549 cells after 6 and 48 h incubation
bands was compared and results are shown as ratios. Values are
Figure 2 Immunocytochemistry findings of collagen type I and HSP47 expression in A549 cells incubated for 48 h with various
concentrations of TGF-β1. Collagen expression: 0 (a), 1 (b), 5 (c), and 10 ng/ml (d) of TGF-β1. HSP47 expression: 0 (e), 1 (f), 5 (g), and 10 ng/ml
(h) of TGF-β1. Original magnification, x400. Positive rates of collagen type I (i) and HSP47 (j) immunostaining of A549 cells after incubation with
TGF-β1 (0, 1, 5, 10 ng/ml) for 48 h. Positive rate of stained cells are significantly increased by TGF-β1 compared with control. Values are
means ± SEM of 5 experiments.
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was assumed at p< 0.05.Results
TGF-β1 enhances the expression of collagen type I and
HSP47 mRNA and protein in A549 cells
We first determined the time course of the TGF-β1
(5 ng/ml) effect on the mRNA expression of collagen
type I and HSP47 in A549 cells. The response of colla-
gen type I to 5 ng/ml of TGF-β1 was maximal after 6,
12, 24 and 72 h of incubation (Figure 1a). TGF-β1 at 5
and 10 ng/ml also significantly increased the expression
of collagen type I mRNA after 6 h of incubation
(Figure 1b). The response of HSP47 to 5 ng/ml TGF-β1
was maximal after 48 and 72 h of incubation (Figure 1c).
Figure 1d shows that TGF-β1 at 5 and 10 ng/ml sig-
nificantly increased HSP47 mRNA expression compared
with untreated controls after 48 h. We next examined
the effects of TGF-β1 on collagen type I and HSP47
protein expression in A549 cells using immunocyto-
chemical staining. We found that 1, 5 and 10 ng/ml of
TGF-β1 increased the number of cells that wereimmunopositive for both collagen type I and HSP47 at
48 h (Figure 2).
Effects of pirfenidone on production of collagen type I
and HSP47 in TGF-β1-stimulated A549 cells
The effect of pirfenidone on TGF-β1-induced expression
of collagen type I and HSP47 mRNA in A549 cells was
analysed by Northern blotting (Figure 3). Incubation
with 500 and 1000 μg/ml of pirfenidone induced sig-
nificant downregulation of collagen type I (6 h) and of
HSP47 (48 h) mRNA expression in A549 cells stimu-
lated by TGF-β1 at 5 ng/ml. Figure 4 shows the
immunocytochemical findings obtained using the anti-
human collagen type I and HSP47 antibodies. Pirfeni-
done significantly decreased the numbers of collagen
type I- and HSP47-immunopositive cells at 100, 500 and
1000 μg/ml, and at 500 and 1000 μg/ml, respectively.
Effects of pirfenidone on EMT in TGF-β1-stimulated A549
cells
Immunocytochemical staining of A549 cells showed
that pirfenidone inhibited the TGF-β1-induced over-
Figure 3 Effects of pirfenidone on collagen type I and HSP47 mRNA expression in A549 cells. Northern blots show that mRNA expression
of collagen type I (a) and HSP47 (b) was inhibited in A549 cells after 6 and 48 h of incubation, with 500 and 1000 μg/ml, respectively, of
pirfenidone and 5 ng/ml of TGF-β1. Density of mRNA bands was normalized against GAPDH mRNA band and is shown as ratios (c and d). Values
are means ± SEM of 4 experiments.
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phenotypic marker (Figure 5a-d). Loss of the epithelial
marker E-cadherin mRNA in A549 cells induced by
TGF-β1 was also normalized by pirfenidone, but thisFigure 4 Immunocytochemistry of collagen type I and HSP47 express
100 (b, f), 500 (c, g), and 1000 μg/ml (d, h) of pirfenidone, respectivel
type I (i) and HSP47 (j) immunostained A549 cells were significantly inhibit
pirfenidone, respectively. Values are means ± SEM of 5 experiments.difference did not reach significance (Figure 5e). In
addition to the changes in the phenotypic markers,
changes in cell morphology were also assessed under
phase contrast light microscopy. Untreated A549 cellsion in A549 cells stimulated with TGF-β1 (5 ng/ml) and 0 (a, e),
y for 48 h. Original magnification: x400. Positive rates for collagen
ed by 100, 500, 1000 μg/ml and by 500 and 1000 μg/ml of
Figure 5 Immunocytochemistry of fibronectin expression in A549 cells stimulated without (a) or with 5 ng/ml (b, c, d) of TGF-β1
without (b), or with 100 (c) or 500 μg/ml (d) of pirfenidone for 48 h. Original magnification: x400. Pirfenidone decreased fibronectin over-
expression induced by TGF-β1. Loss of epithelial marker E-cadherin mRNA in A549 cells caused by TGF-β1 (5 ng/ml) was also normalized by
pirfenidone, but the difference did not reach significance (e).
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cells show a spindle-like mesenchymal shape. Pirfeni-
done partially suppressed TGF-β1-induced mesenchy-
mal morphology (Figure 6).
Discussion
The major finding of the present study was that TGF-β1
enhanced HSP47 and collagen type I synthesis in A549
cells at both the mRNA and protein levels and that pir-
fenidone directly inhibited these effects.
The collagen-binding, stress-inducible protein, HSP47,
acts as a collagen-specific molecular chaperone in the
intracellular processing of procollagen [21-23]. In a mur-
ine model of bleomycin-induced pulmonary lungfibrosis, HSP47 mRNA and protein expression predom-
inantly increased in α-SMA-positive myofibroblasts of
the lung interstitium, and the relative amounts of HSP47
mRNA in the lung significantly correlated with the
hydroxyproline content [12,27]. In addition to fibro-
blasts, type II pneumocytes in this mouse model
expressed HSP47, suggesting that type II pneumocytes
also contribute to lung fibrosis [12]. The expression of
type I procollagen and HSP47 was also significantly
higher in type II pneumocytes identified in surgical bi-
opsy specimens from patients with idiopathic usual
interstitial pneumonia (UIP) than in those from patients
with collagen vascular disease-associated UIP and idio-
pathic nonspecific interstitial pneumonia [26], which
Figure 6 Effects of pirfenidone on morphological changes stimulated by TGF-β1 for 48 h in A549 cells. (a) Untreated A549 cells show a
pebble-like epithelial shape (a) and TGF-β1-treated cells show a spindle-like mesenchymal shape (b). Pirfenidone partially suppresses TGF-β1-
induced mesenchymal morphology (c).
Hisatomi et al. BMC Pulmonary Medicine 2012, 12:24 Page 7 of 9
http://www.biomedcentral.com/1471-2466/12/24have better prognoses than idiopathic UIP [30]. These
findings suggest that in addition to fibroblasts, type II
pneumocytes also directly contribute to lung fibrosis
thorough collagen and HSP47 synthesis.
Pirfenidone exerts both anti-inflammatory and anti-
fibrotic activities in animal models of pulmonary fibro-
sis induced by bleomycin [9-12] and cyclophosphamide
[13]. These studies in vivo showed that pirfenidone ob-
viously reduced the histological and biochemical signs
of lung fibrosis including the hydroxyproline content.
Pirfenidone also decreased the levels of pulmonary pro-
tein and gene expression of some fibrogenic cytokines
such as TGF-β1 [10] and platelet-derived growth factor
(PDGF) [14]. Our recent study in vitro showed that
pirfenidone directly inhibits collagen type I and HSP47
expression in TGF-β1-stimulated human lung fibro-
blasts [20]. Together, these findings indicate the po-
tential of pirfenidone as a novel, broad-spectrum
anti-fibrotic agent. In addition, pirfenidone suppresses
the increased expression of HSP47 in our mouse model
of lung fibrosis [12], suggesting that this drug could
change the fibroblast phenotype. Here, we demon-
strated a similar inhibitory effect of pirfenidone on col-
lagen type I and HSP47 in A549 cells at both the
protein and mRNA levels in vitro, confirming that the
effect of pirfenidone on collagen and HSP47 in vivo
represented a direct effect on type II pneumocytes. In
addition to its anti-inflammatory action, pirfenidone
might act as an anti-fibrotic agent for patients with IPF
by directly inhibiting HSP47 and collagen production
in type II pneumocytes as well as in fibroblasts in the
human lung. In this context, our immunocytochemical
study of collagen I showed that pirfenidone co-
administration significantly reduced the ratio (%) of
positive cells at 100 μg/ml and significantly inhibitedTGF-β1-enhanced HSP47 and collagen type I mRNA
expression at 500 μg/ml. This suggests that pirfenidone
acts as an anti-fibrotic agent by directly inhibiting both
HSP47 and collagen type I mRNA expression, which
results in reduced collagen synthesis in type II pneu-
mocytes. In support of this proposal, HSP47 inhibition
by antisense oligodeoxynucleotides obviously suppresses
collagen production in 3 T6 cells [23], experimental
proliferative glomerulonephritis [31] and in peritoneal
fibrosis [32], indicating that HSP47 is a promising tar-
get for the treatment of fibrotic diseases including IPF.
This study thus identified pirfenidone as the first
known agent that can control HSP47 and collagen ex-
pression in type II pneumocytes.
Recent evidence from studies of pulmonary fibrosis
supports the role of EMT in the development of fibro-
blastic foci in IPF [2]. Yao and colleagues [33] showed
that TGF-β1 induces EMT in alveolar epithelial cells
from SD rats. Kasai and colleagues also reported that
TGF-β1, but not TNF-α or interleukin-1β, induced A549
cells to undergo EMT [3]. Willis and colleagues also
demonstrated that cultures of primary rat alveolar epi-
thelial cells and a rat alveolar epithelial cell line undergo
EMT in response to TGF-β1 stimulation [5]. Kim et al.
also reported that the main source of mesenchymal ex-
pansion is lung epithelial cells from a mouse model of
pulmonary fibrosis in vivo [4]. The induction of EMT is
characterized by the expression of α-SMA, transform-
ation of myofibroblast morphology, the increased forma-
tion of stress fibers by F-actin reorganization, and loss of
the epithelial marker E-cadherin. Collagen type I and
HSP47 expression is also considered to be one of the
useful parameters for recognizing EMT [28]. These re-
cent findings and our present data demonstrate that
EMT develops in alveolar epithelial cells mediated by
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an important mechanism of myofibroblast production
during pulmonary fibrosis. In addition, the present data
showed that the over-expression of collagen type I,
HSP47 and fibronectin induced by TGF-β1 in A549 cells
was inhibited by pirfenidone. TGF-β1-induced loss of
E-cadherin in A549 cells was also normalized by pirfe-
nidone while this difference was not significant. In
addition, pirfenidone inhibited a mesenchymal morph-
ology induced by TGF-β1. These suggest that pirfeni-
done might partially inhibit EMT.
Conclusion
The anti-fibrotic effects of pirfenidone might be
mediated not only through the direct inhibition of colla-
gen type I expression but also through the inhibition of
HSP47 expression in alveolar epithelial cells, which
results in reduced collagen synthesis in lung fibrosis.
Furthermore, pirfenidone might partially inhibit the
epithelial-mesenchymal transition.
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